SCHEMBL2175029

SCHEMBL2175029

COC(=O)Cc1cc(OCc2ccccc2)c2cc(F)ccc2c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 1/20 0.43
FFAR4 Q5NUL3 2/20 0.42
BRD4 O60885 2/20 0.42
MRGPRX4 Q96LA9 1/20 0.42
FFAR1 O14842 1/20 0.42
PPIA P62937 1/20 0.42
PLA2G2A P14555 2/20 0.42
MTNR1A P48039 1/20 0.42
MTNR1B P49286 1/20 0.42
LRRK2 Q5S007 1/20 0.41
PPARG P37231 1/20 0.41
PTGER1 P34995 1/20 0.41
HSP90AB1 P08238 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27841440 0.88 PTGDR2 (0.48) LMNAMAPTL3MBTL1NPC1FFAR4
SCHEMBL2172690 0.86 PTGER1 (0.47) NPC1BRD4MRGPRX4PPIAPTGER1
SCHEMBL2173086 0.82 LMNA (0.54) LMNAMAPTL3MBTL1NPC1FFAR4
SCHEMBL27822158 0.82 ALDH1A1 (0.52) LMNAMAPTL3MBTL1NPC1FFAR4
SCHEMBL28085585 0.82 FFAR4 (0.49) LMNAMAPTL3MBTL1NPC1FFAR4
SCHEMBL2172046 0.81 LIPE (0.41) LMNAMAPTL3MBTL1NPC1MRGPRX4
SCHEMBL2176856 0.80 MRGPRX4 (0.43) LMNAMAPTL3MBTL1NPC1FFAR4
SCHEMBL31667762 0.79 PTGER1 (0.56) MRGPRX4PTGER1
SCHEMBL25245694 0.79 HSP90AB1 (0.51) LMNAMAPTL3MBTL1NPC1BRD4
SCHEMBL2172852 0.79 L3MBTL1 (0.41) LMNAMAPTL3MBTL1NPC1MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2791111-B1 [4-(PIPERIDIN-4-YL)-NAPHTHALEN-2-YL]-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS FOR THE TREATMENT OF RESPIRATORY DISORDERS HOFFMANN LA ROCHE (CH) 2017-01-18 EP disclosed
EP-2791111-A1 PIPERIDINYL NAPHTHYLACETIC ACIDS F.HOFFMANN-LA ROCHE AG (CH) 2014-10-22 EP disclosed
US-8642629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2014-02-04 US disclosed
US-8642629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2014-02-04 US disclosed
US-8642629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2014-02-04 US disclosed
EP-2358677-B1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
EP-2358677-B1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
WO-2013087544-A1 PIPERIDINYL NAPHTHYLACETIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2013-06-20 WO disclosed
US-20130150407-A1 PIPERIDINYL NAPHTHYLACETIC ACIDS HOFFMANN-LA ROCHE INC. (US) 2013-06-13 US disclosed
EP-2346819-B1 NAPHTHYLACETIC ACIDS HOFFMANN LA ROCHE (CH) 2013-04-10 EP disclosed
US-20100125061-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-05-20 US disclosed
US-20100125061-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-05-20 US disclosed
US-20100125061-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-05-20 US disclosed
WO-2010055004-A1 NAPHTHYLACETIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed
US-20100125058-A1 NAPHTHYLACETIC ACIDS CHEN LI 2010-05-20 US disclosed
US-20100125058-A1 NAPHTHYLACETIC ACIDS CHEN LI 2010-05-20 US disclosed
US-20100125058-A1 NAPHTHYLACETIC ACIDS CHEN LI 2010-05-20 US disclosed
WO-2010055004-A1 NAPHTHYLACETIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed
WO-2010055006-A1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed
WO-2010055006-A1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125058-A1 NAPHTHYLACETIC ACIDS HRH2, HRH1, HRH3 LMNA 1698/4885MAPT 4671/4885L3MBTL1 4726/4885
US-20100125061-A1 NAPHTHYLACETIC ACIDS HRH2, HRH1, HRH3 LMNA 1535/4885MAPT 4646/4885L3MBTL1 4773/4885
US-20130150407-A1 PIPERIDINYL NAPHTHYLACETIC ACIDS HRH2, HRH1, HRH3 LMNA 1827/4885MAPT 4620/4885L3MBTL1 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.